
PE2 (Prime Editor 2)
$2,400.00 - $4,800.00
All products have special prices for bulk purchase, please contact for more details if required.
Cat. No.: PE2-500 (for 500pmol)
Cat. No.: PE2-2500 (for 2500pmol)
Description
PE2 (Prime Editor 2) is the core component of the pioneering prime‑editing system, enabling precise genome modifications without introducing DNA double‑strand breaks. PE2 is a fusion protein composed of the SpCas9(H840A) nickase and an engineered Moloney murine leukemia virus reverse transcriptase (M‑MLV RT). The Cas9 module carries the H840A point mutation, which specifically inactivates the HNH nuclease domain while retaining RuvC activity. As a result, the enzyme introduces a single‑strand nick on the non‑complementary DNA strand under pegRNA guidance.
The fused M‑MLV reverse transcriptase contains five key amino‑acid substitutions that significantly enhance its thermostability, processivity, and template‑binding affinity. These improvements allow PE2 to efficiently synthesize the edited DNA sequence directly at the nick site.
Prime editing enables all 12 possible base‑to‑base conversions, as well as precise small insertions and deletions, without requiring donor DNA templates or generating hazardous double‑strand breaks. This greatly reduces the risk of off‑target mutations and chromosomal rearrangements. Compared with the first‑generation PE1 system, PE2 achieves a 2.3‑ to 5.1‑fold increase in editing efficiency due to the optimized reverse transcriptase, establishing a strong foundation for broad applications in basic research, gene therapy, and crop engineering.
- Precise Point Mutation Correction: Correcting pathogenic single‑nucleotide variants with high accuracy.
- Small Fragment Insertion: Introducing short tags, regulatory elements, or functional motifs.
- Precise Deletion: Removing small harmful DNA segments without inducing double‑strand breaks.
- Disease Modeling: Introducing disease‑associated mutations to generate accurate cellular or animal models.
- Functional Studies: Investigating the biological effects of specific mutations.
- Preclinical Gene‑Therapy Research: Evaluating prime‑editing–based correction strategies for inherited disorders.
SBS Genetech is recognized as one of the global major leading industry players in Gene Editing by third-party market researchers. For more details, please visit Global Gene Editing Service Market 2019 by Company, Regions, Type and Application, Forecast to 2024.
Related:
- Synthetic sgRNAs
- Cas12a Nuclease (Lyophilized)
- Cas12b Nuclease (Lyophilized)
- Cas13a Nuclease (Lyophilized)
- Cas14a1 Nuclease (Lyophilized)
- SpCas9 Nuclease (Lyophilized)
- SuCas12a2 Nuclease (Lyophilized)
- dCas9 NLS (Lyophilized)
- EiCsm6 (Lyophilized)
- LwaCas13a Nuclease (Lyophilized)
- BrCas12a Nuclease (Lyophilized)
- AsCas12a Nuclease (Lyophilized)
- Cas9 Nuclease (with NLS)
- Cas9 HF-NLS (SpCas9 HF-NLS)
- CRISPR-dCas9 Nuclease
- dCas9 NLS
- spCas9
- SpdCas9
- spCas9-NG
- SpRYCas9
- Cas9 Nickase (H840A) NLS
- Cas9 Nickase (D10A) NLS
- TsCas12a
- OsCas12a
- HkCas12a
- BoCas12a
- AsCas12a
- FnCas12a
- LbCas12a (Cpf1) Nuclease
- Enhanced LbaCas12a (Cpf1)
- Lb5Cas12a (Cpf1) Nuclease
- SuCas12a2 Nuclease
- AaCas12b
- AacCas12b
- AapCas12b
- BrCas12b
- LwCas13a
- LbuCas13a
- LtrCas13a (C2c2) Nuclease
- LwaCas13a (C2c2) Nuclease
- EiCsm6
- HheCas13a (C2c2)
- TccCas13a (C2c2)
- YmeCas12a (Cpf1)
- CmeCas12a (Cpf1)
- Enhanced LbCas12a
- PfAgo
- TtAgo
- T7 Endonuclease I










